

CRP-Kinetik sagt das Immuntherapieansprechen beim metastasierten Nierenzell- und Urothelkarzinom voraus

Niklas Klümper, Jonas Saal, Danijel Sikic, Markus Eckstein

Literatur

1. Fukuda S et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. *J Immunother Cancer* 2021; 9
2. Klümper N et al. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. *Clin Transl Immunology* 2021; 10: e1358
3. Klümper N et al. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. *Eur J Cancer* 2022; 167: 13-22
4. Klümper N et al. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. *J Immunother Cancer* 2022; 10: e004024